While these technologies are now a therapeutic reality, the ASGCT 2024 annual meeting this week was a reminder of just how ...

Anticipating approval for its COPD therapy ensifentrine, Verona has entered into a $650 million financing deal with Oaktree ...

Launched in 2021, the public-private consortium on Wednesday updated ASGCT attendees on its efforts to bring adeno-associated ...

ASGCT 2024 session, CBER Director Peter Marks made the case for a better, “more convergent” global framework on cell and gene ...

Takeda saw a 57% drop in profit in its 2023 fiscal year and has lowered its outlook for the coming fiscal year, mostly driven ...

Novavax Soars on $1.4B Deal With Sanofi for COVID Vaccine - read this article along with other careers information, tips and ...

With its $525 million investment, Royalty Pharma will acquire the royalties and milestones for ImmuNext’s anti-CD40 therapy ...

The Bay Area–based biotech plans to use the funds to advance two lead programs, one to treat atopic dermatitis and another ...

An autologous and personalized regulatory T cell therapy is safe in patients with type 1 diabetes, but does not help preserve ...

Jeffrey Chamberlain, president of the American Society of Gene & Cell Therapy, spoke with BioSpace about what we can expect ...

Cell and gene therapy company Cellectis announced Monday it has completed a $140 million investment from AstraZeneca that ...

With three FDA approvals in the past 10 months, there is a lot of momentum in the Duchenne muscular dystrophy space. Here are ...